Improved survival for patients with lung cancer treated with perioperative immunotherapy.

Competing Interests: CJP reports honoraria from BMS, Regeneron, and Jazz Pharmaceuticals, and research funding from the BMS Foundation and Rising Tide Foundation. DHO reports support from AstraZeneca, Amgen, and Genentech for travel and research funding to institution from BMS, Merck, Palobiofarma, Genetech, AbbVie, Nuvalent, and Onc.AI. The views expressed are those of the authors only, and not representative of the National Comprehensive Cancer Network or the American Society of Clinical Oncology guidelines.